High pathological responses in borderline resectable NSCLC patients after induction with dual immunotherapy and concurrent chemoradiotherapy Presented ByDr Idris Bahce, Amsterdam UMC, the Netherlands TrialPhase 2, INCREASE ConferenceESMO 2022 TypePeer-reviewed article 16 November 2022 18:05